OCUL250117C17500
- 0.06
- 0.000.00%
Ocular Therapeutix Newsroom
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $18
Ocular Therapeutix (OCUL) Receives a Buy From Bank of America Securities
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $21
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Baxter International (BAX) and Ocular Therapeutix (OCUL)
Ocular Therapeutix Analyst Ratings
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Promising Outlook for Ocular Therapeutix: Buy Rating Supported by Strong Market Demand and Financial Valuation
Scotiabank Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $22
Ocular Therapeutix (OCUL) Gets a Buy From Scotiabank
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $15
Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $18
TD Cowen Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $14
Ocular Therapeutix's Clinical Progress and Strategic Trials Drive Buy Rating
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Remains a Buy on Ocular Therapeutix (OCUL)
Baird Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $17
Ocular Therapeutix Initiated With an Outperform at Scotiabank
Ocular Therapeutix Analyst Ratings
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $14